Pharma channel feed

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' com­pe­ti­tion

5 years ago
Coronavirus

Bio­gen's last-ditch pitch for an in­junc­tion to pro­tect Tec­fidera is de­nied, paving way for My­lan gener­ic

5 years ago

Genen­tech slash­es near­ly 500 jobs in strate­gic shift to 'lo­cal health­care ecosys­tems.' Clin­i­cal spe­cial­ists make up the biggest group

5 years ago
R&D

Mod­er­na, Pfiz­er be­gin to give glimpse of Covid-19 vac­cine pric­ing — and prof­its

5 years ago
Coronavirus

Af­ter down year, 2020 brings new cash in­to Mass­a­chu­setts biotech

5 years ago
Financing

Trump looks to ham­mer down drug prices with 4 ex­ec­u­tive or­ders

5 years ago

So­bi's high-pri­or­i­ty rare dis­ease drug runs in­to a wall at EMA

5 years ago
FDA+

Could a patent rul­ing threat­en Mod­er­na’s Covid-19 vac­cine?

5 years ago

As­traZeneca COPD drug fi­nal­ly gets OK from FDA, inch­ing clos­er to GSK leader

5 years ago
FDA+

The phar­ma world's cham­pi­on patent wall builder is called out for their 'drip-feed' strat­e­gy to safe­guard the next megablock­buster fran­chise

5 years ago
Bioregnum
Opinion

Sanofi con­tin­u­ing with API spin­off de­spite French on-shoring push, ten­sions with union — Reuters

5 years ago

In an­tic­i­pa­tion of PhI­II tri­al re­sults, Am­i­cus pares down old debt with $400 mil­lion loan

5 years ago
R&D

Top biotech an­a­lyst projects a gloomy out­look for Pfiz­er's JAK port­fo­lio

5 years ago

Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ap­proval

5 years ago
R&D

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

5 years ago

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

5 years ago
Bioregnum
Coronavirus

No­var­tis pays $678M for kick­back scheme as Vas Narasimhan tries to dis­tance phar­ma gi­ant from shady be­hav­ior

5 years ago

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

5 years ago
FDA+

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

5 years ago
Deals
R&D

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

5 years ago
FDA+

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

5 years ago
People
R&D

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

5 years ago
FDA+

Take­da takes a $200M hit af­ter No­var­tis is forced to yank its mar­ket­ing ap­pli­ca­tion for Xi­idra

5 years ago
FDA+

Gilead opts for $3,120 US in­sur­er price for Covid-19 drug remde­sivir — but some say it should be free

5 years ago
First page Previous page 252253254255256257258 Next page Last page
A service from the Financial Times